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Mutations within PCSK9 (proprotein convertase subtilisin/
kexin type 9) are associated with dominant forms of familial
hyper- and hypocholesterolemia. Although PCSK9 controls low
density lipoprotein (LDL) receptor (LDLR) levels post-tran-
scriptionally, several questions concerning its mode of action
remain unanswered. We show that purified PCSK9 protein
added to themedium of human endothelial kidney 293, HepG2,
and Chinese hamster ovary cell lines decreases cellular LDL
uptake in a dose-dependentmanner. Using this cell-based assay
of PCSK9 activity, we found that the relative potencies of several
PCSK9 missense mutants (S127R and D374Y, associated with
hypercholesterolemia, and R46L, associated with hypocholes-
terolemia) correlate with LDL cholesterol levels in humans car-
rying such mutations. Notably, we found that in vitro wild-type
PCSK9 binds LDLR with an 150-fold higher affinity at an
acidic endosomal pH (KD  4.19 nM) compared with a neutral
pH (KD 628 nM). We also demonstrate that wild-type PCSK9
andmutants S127R and R46L are internalized by cells to similar
levels, whereas D374Y is more efficiently internalized, consist-
ent with their affinities for LDLR at neutral pH. Finally, we show
that LDL diminishes PCSK9 binding to LDLR in vitro and par-
tially inhibits the effects of secreted PCSK9 on LDLR degrada-
tion in cell culture. Together, the results of our biochemical and
cell-based experiments suggest a model in which secreted
PCSK9 binds to LDLR and directs the trafficking of LDLR to the
lysosomes for degradation.
PCSK9 (proprotein convertase subtilisin/kexin type 9)
encodes the ninth member of the mammalian proprotein con-
vertase family of serine endoproteases. PCSK9 is translated as a
692-amino acid proprotein that includes several domains found
in other proprotein convertases, including anN-terminal signal
sequence, a prodomain, a catalytic domain, and a cysteine-rich
C-terminal domain (1–3). The PCSK9 catalytic domain shares
high sequence similarity with the proteinase K family of subti-
lases and contains a catalytic triad (Asp186, His226, and Ser386)
responsible for autoprocessing (1, 4). PCSK9 processing occurs
in the secretory pathway, presumably in the endoplasmic retic-
ulum, and results in proteolytic cleavage occurring after Gln152
(FAQ2SIP). This cleavage generates a stable PCSK9 het-
erodimer composed of a 14-kDa prodomain fragment and a
mature 57-kDa fragment containing the catalytic and C-termi-
nal domains (4, 5). Following processing, the PCSK9 het-
erodimer exits the ER and is eventually secreted (1). The prodo-
main of PCSK9 remains strongly bound to the mature protein
after secretion, presumably inhibiting the catalytic activity of
PCSK9 (1, 5, 6). To date, there is no conclusive evidence that the
processed secreted form of PCSK9 can cleave any substrates in
a catalytic serine-dependent manner.
The first evidence that PCSK9 plays a significant role in reg-
ulating plasma low density lipoprotein (LDL)3 cholesterol
(LDL-C) levels was the identification of several missense muta-
tions in PCSK9 resulting in a form of autosomal dominant
hypercholesterolemia (7–9). Mutations within the prodomain
(S127R) or catalytic domain (F216L and D374Y) are associated
with high levels of circulating LDL-C. In addition to PCSK9
mutations that result in hypercholesterolemia, two large
genetic studies identified two nonsense mutations (Y142X and
C679X) and several missense mutations (R46L, L253F, and
A443T) in PCSK9 that are associatedwith hypocholesterolemia
(10–12). Notably, humans that are heterozygous for either the
Y142X or C679X truncation mutation have a 30–40% reduc-
tion in plasma LDL-C and an 88% reduction in the risk of cor-
onary heart disease (13). In comparison, humans heterozygous
for the R46Lmissensemutation have a 15% reduction in LDL-C
and a 47% reduction in cardiovascular disease (13). Based on
their relative effects on plasma LDL-C concentrations in
humans and the fact that certain PCSK9 mutations (S127R,
F216L, and D374Y) cause dominant hypercholesterolemia,
PCSK9 mutations have been classified as either loss-of-func-
tion (Y142X, C679X, and R46L) or gain-of-function (S127R,
F216L, and D374Y) mutations.* The costs of publication of this articlewere defrayed in part by the paymentof page charges. This article must therefore be hereby marked “advertise-
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Several lines of evidence demonstrate that PCSK9 lowers the
amount of hepatic LDL receptor (LDLR) protein and thus com-
promises the liver’s ability to remove LDL-C from the circula-
tion. Adenovirus-mediated overexpression of PCSK9 in the liv-
ers of mice results in the accumulation of circulating LDL-C
because of a dramatic loss of hepatic LDLR protein, with no
effect on LDLR mRNA levels (5, 14–16). The effect of PCSK9
overexpression on raising circulating LDL-C levels in mice is
completely dependent on the expression of LDLR, again indi-
cating that the regulation of LDL-C by PCSK9 is mediated
through down-regulation of LDLR protein. In agreement with
these findings, mice lacking PCSK9 or in which PCSK9 mRNA
has been lowered by antisense oligonucleotide inhibitors have
higher levels of hepatic LDLR protein and a greater ability to
clear circulating LDL-C (17, 18). In addition, lowering PCSK9
levels in cultured human hepatocytes by small interfering RNA
also results in higher LDLR protein levels and an increased abil-
ity to take up LDL-C (5, 16). Together, these data indicate that
PCSK9 action leads to increased LDL-C by lowering LDLR pro-
tein levels.
Although PCSK9 post-transcriptionally reduces the
amount of LDLR, the mechanism and site of PCSK9 action
remain unresolved. Recent observations indicate that
PCSK9 can regulate LDLR protein levels both during and
after secretion (6, 19). Moreover, a recent study has demon-
strated using non-quantitative gel-based methods that
PCSK9 binds specifically to LDLR and that the gain-of-func-
tion mutant D374Y shows increased binding in vitro (6). In
this study, we compare the effects of processed secreted
forms of wild-type PCSK9, gain-of-function mutants D374Y
and S127R, and loss-of-function mutant R46L on cellular
LDL uptake as a measure of LDLR function. Using surface
plasmon resonance (Biacore) experiments, we also obtained
kinetic and thermodynamic binding constants for the inter-
action between LDLR and wild-type and S127R, D374Y, and
R46L mutant PCSK9. Our functional and biochemical data
collectively suggest a mechanism whereby processed
secreted PCSK9 binds to LDLR and likely prevents LDLR
cell-surface recycling by directing the receptor to the lyso-
somes for degradation.
EXPERIMENTAL PROCEDURES
Construction ofWild-type andMutant PCSK9 Expression
Vectors
The PCSK9 gene was amplified from human fetal liver
QUICK-Clone cDNA (BD Biosciences). The following primers
were used for the pre-amplification of the PCSK9 cDNA:
5-GCAACCTCTCCCCTGGCCCTCATG-3 (forward) and
5-GCTTCCTGGCACCTCCACCTGGGG-3 (reverse). This
PCSK9 gene product was used as a template for TOPO TA
primers to generate the final PCSK9 sequence. The primers for
TOPO TA cloning were 5-CCACCATGGGCACCGTCAGC-
TCCAGG-3 (forward) and 5-CTGGAGCTCCTGGGAGGC-
CTGCGCCAG-3 (reverse). The final PCSK9 insert was ligated
into a TOPO TA vector using a pcDNA3.1/V5-His-TOPO-TA
expression kit (Invitrogen), followed by transformation into
chemically competent TOP10 Escherichia coli cells. Clones
were selected and checked for the correct insert by gel electro-
phoresis. Based on sequence analysis of this clone, it is impor-
tant to note that this sequence has the more common form of
the two natural mutations I474V and E670G andmatches Gen-
BankTM accession number AX207686. The plasmid containing
wild-type PCSK9with C-terminal V5 andHis tags is referred to
as pcDNA3.1-F1-WT.
To generate plasmids expressing mutant forms of human
PCSK9, site-directed mutagenesis was performed using the
QuikChange II XL site-directed mutagenesis kit (Stratagene).
The following primers were used to generate mutations: for
plasmid pcDNA3.1-F1-S386A, 5-CACAGAGTGGGACAG-
CACAGGCTGCTGCCCAC-3 (forward) and 5-GTGGG-
CAGCAGCCTGTGCTGTCCCACTCTGTG-3 (reverse); for
plasmid pcDNA3.1-F1-S127R, 5-CTGGTGAAGATGAG-
GGGCGACCTGCTGG-3 (forward) and 5-CCAGCAGG-
TCGCCCCTCATCTTCACCAG-3 (reverse); for plasmid
pcDNA3.1-F1-D374Y, 5-CATTGGTGCCTCCAGCTACTG-
CAGCACCTGC-3 (forward) and 5-GCAGGTGCTGCAGT-
AGCTGGAGGCACCAATG-3 (reverse); and for plasmid
pcDNA3.1-R46L, 5-CTGGTGCTAGCCTTGCTGTCCG-
AGGAGGACGGCC-3 (forward) and 5-GGCCGTCCTC-
CTCGGACAGCAAGGCTAGCACCAG-3 (reverse). All
PCSK9 constructs described were present in a pcDNA3.1
backbone with G418 selection and C-terminal V5 and His
tags (Invitrogen).
Stable Transfection of Human Embryonic Kidney (HEK) 293
Cells
HEK293 cells were plated at a density of 1.8  106 cells/6-
well container in 1 Dulbecco’s modified Eagle’s medium
(DMEM;Mediatech, Inc.) containing 100 units of penicillin and
100 g/ml streptomycin sulfate and supplemented with 10%
fetal bovine serum (FBS). The following day, cells were trans-
fected with 6 g of wild-type or mutant plasmid DNA per con-
tainer using FuGENE 6 transfection reagent (Roche Applied
Science) according to the manufacturer’s instructions. A rea-
gent/plasmid DNA ratio of 6:1 was used for transfections. To
generate a control stable cell line, 6g of pcDNA3.1was used to
transfect HEK293 cells. After 2 days, the medium was changed
to 1 DMEM containing 1 mg/ml G418 and supplemented
with 10% FBS, and cells were maintained in this medium.
Western Blot Analysis
PCSK9 Western Blot Analysis—Cells carrying vector alone
(pcDNA3.1) or vector plus PCSK9 (pcDNA3.1-F1-WT,
pcDNA3.1-F1-R46L, pcDNA3.1-F1-S127R, and pcDNA3.1-F1-
D374Y) were plated in 1 DMEM containing 1 mg/ml G418
and supplemented with 10% FBS. After 24 h, the medium was
switched to DMEM lacking serum. After an additional 6 h, the
mediumwas removed, and the cells were lysed in radioimmune
precipitation assay buffer (Teknova) plus Complete protease
inhibitor mixture (Roche Applied Science). Protein concentra-
tionwas assayed using a BCAprotein assay kit (Pierce). 10g of
proteins from lysate or 15 l of medium was loaded onto
10–20% Tris/glycine gels (Invitrogen). Following transfer,
membranes were successively incubated with anti-V5 primary
antibody (1:5000; Invitrogen) and alkaline phosphatase-conju-
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gated anti-mouse IgG (H  L) (1:3000; Promega). Bands were
subsequently detected using a one-step nitro blue tetrazolium/
5-bromo-4-chloro-3-indolyl phosphate kit (Pierce) according
to the manufacturer’s instructions.
LDLRWestern Blotting—HEK293 cells carrying vector alone
(pcDNA3.1) were plated in a 24-well plate in 1 DMEM con-
taining 1 mg/ml G418 and supplemented with 10% FBS. After
24 h, the medium was switched to DMEM lacking serum. Cells
were further incubated for 24 h without serum, and each well
containing1.2 105 cells was lysed in 160l of radioimmune
precipitation assay buffer. Lysate (40 l) was loaded onto
4–12% NuPAGE gel (Invitrogen). Following transfer, mem-
branes were incubated with rabbit anti-human LDLR antibody
(Research Diagnostics Inc.) and horseradish peroxidase-
conjugated anti-rabbit IgG (H L) (Cell Signaling Technol-
ogy). Bands were subsequently detected using an ECL kit
(Amersham Biosciences) according to the manufacturer’s
instructions.
PCSK9 Purification
The medium generated from one cell factory was stored at
4 °C.TALON immobilizedmetal affinity chromatography resin
(10 ml; Clontech) was added and rocked at room temperature
for 1 h on an Adams Nutator. Resin was collected by gravity
filtration and bulk-washed according to reagent instructions.
Less than 10mgof eluted protein (concentration determinedby
absorbance at 280 nmusing aNanoDropND-1000 spectropho-
tometer) was loaded onto a Superdex 200 10/300GL size exclu-
sion column (GEHealthcare) run in buffer A (25mMHEPES, 30
mM NaCl, 0.1 mM CaCl2, and 5% glycerol, pH 7.90). Peak frac-
tions were loaded onto a 6-ml RESOURCE Q column (GE
Healthcare). A 6.0 ml/min linear gradient of 0–50% elution
buffer A plus 1.0 M NaCl in a volume of 120 ml was used. Peak
fractions were concentrated using a Centricon Centriplus-5
concentrator (Millipore) to concentrations of 1 mg/ml and
stored at20 °C. For Biacore studies, proteins were purified by
immobilized metal affinity chromatography and then loaded,
after extensive dialysis, onto a RESOURCE Q column. Peak
fractions were pooled and loaded onto a Superdex 200 20/60
size exclusion column (GE Healthcare) run in 25 mM HEPES,
150mMNaCl, 0.1mMCaCl2, and 10% glycerol, pH 7.9. Concen-
trated proteins (up to 10 mg/ml) were stored at80 °C.
Isolation of LDL
Blood for LDL isolation was obtained from healthy human
volunteers. Blood (200 ml) was collected in EDTA tubes and
spun at 15,000 rpm for 15 min at 4 °C. Plasma density was
adjusted to 1.02 g/ml with sodium bromide, and the tubes were
centrifuged at 45,000 rpm in a Ti-70 ultracentrifuge rotor for
20 h. The very LDL (VLDL) layer was removed, and the bottom
layer was adjusted to a density of 1.063 g/ml with sodium bro-
mide. The tubeswere again centrifuged at 45,000 rpm in aTi-70
rotor for 72 h. The LDL layer was removed and dialyzed against
phosphate-buffered saline, pH 7.4, and 1 mM EDTA. The final
protein concentration was determined using the BCA protein
assay kit.
Labeling of LDL, PCSK9, LDLR, and Anti-V5 Antibody
LDL was labeled with a fluorescent 3,3-dioctadecylindocar-
bocyanine (DiI) particle (Molecular Probes). A stock solution
containing 3 mg of DiI dissolved in 1 ml of Me2SO was pre-
pared. This stock solution of DiI was added to LDL at a final
concentration of 135 g of DiI to 1 ml of LDL (1 mg/ml). The
labeling reaction was incubated at 37 °C for 24 h in the dark,
followed by LDL isolation as described above.
PCSK9protein and anti-V5 antibodywere labeledwithAlexa
Fluor 647. Prior to labeling, proteins (0.5–2 mg/ml) were buff-
er-exchanged into 100 mM sodium carbonate and 200 mM
NaCl, pH 8.6, at 4 °C using D-Tube dialyzers (Calbiochem).
Proteinswere then reactedwith either 5 (PCSK9) or 10 (anti-V5
monoclonal antibody) molar eq of Alexa Fluor 647-labeled
N-hydroxysuccinimide (Invitrogen) that had been dissolved in
Me2SO at 10 mg/ml. Alexa Fluor 647 was added, and the solu-
tion briefly was vortexed and allowed to stand at 4 °C for at least
4 h protected from light. The reaction was quenched by the
addition of 1.0 M Tris, pH 8.0, to a final concentration of at least
10mM for 30min. Purification from free dyewas achieved using
a NAP-5 column (GE Healthcare) pre-equilibrated in 50 mM
potassiumphosphate and 350mMNaCl, pH7.0, and elutedwith
the same buffer. Protein concentration and extent of dye incorpo-
ration were determined by measuring the relative absorbance at
280 and 651nmand the extinction coefficients for theAlexa Fluor
647 dye provided by themanufacturer. Labeled proteins were sta-
bilized by the addition of bovine serum albumin (BSA; Sigma) to a
final concentration of 0.05% (w/v).
Soluble LDLR (R&D Systems) was labeled with europium as
described below. Lyophilized soluble LDLR (50 g, 560 pmol)
was solubilized in 100 l of 100 mM sodium carbonate and 200
mM NaCl, pH 8.6, and dialyzed against the same buffer at 4 °C
usingD-Tube dialyzers. Thematerial was combinedwith 7.1l
of a 10 mg/ml solution of Europium (W1024) isothiocyanate
(Eu-W1024-ITC) (PerkinElmer Life Sciences) dissolved in
water (71g, 10 nmol, 20 eq). Labeling was carried out for16
h at 4 °C protected from light; quenched by the addition of 1.0 M
Tris, pH 8.0, to a final concentration of 100 mM for 15 min; and
brought to a total volume of 100 l with 50 mM potassium
phosphate and 350 mM NaCl, pH 7.0. Purification from free
europium was achieved using a two-step process: 1) rapid
buffer exchange using a Bio-Spin 30 column (Bio-Rad) pre-
equilibrated in 50 mM potassium phosphate and 350 mMNaCl,
pH 7.0, immediately followed by the addition of a 5% (w/v) BSA
stock to a final concentration of 0.05%; and 2) further purifica-
tion by a NAP-5 column pre-equilibrated in 50 mM potassium
phosphate, 350 mM NaCl, pH 7.0, and 0.05% BSA and elution
with the same solution. Because of the low amounts of soluble
LDLR, available protein concentration was not determined
explicitly. Time-resolved fluorescence resonance energy trans-
fer (TR-FRET) experiments described below are reported using
the maximum concentration assuming 100% recovery from
labeling.
DiI-labeled LDL Uptake Assay
HEK293 cells stably expressing the pcDNA3.1 vector alone
were plated in a 96-well poly-D-lysine-coated plate (Corning) at
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a density of 30,000 cells/well in 1DMEM containing 1mg/ml
G418 and 10% FBS. A similar plating protocol was followed for
HepG2 and Chinese hamster ovary (CHO) cells, except that
G418was not added to themedium.After 24 h, themediumwas
switched to either DMEM lacking serum or containing 10%
lipoprotein-deficient serum (Intracel), with either protocol
yielding similar potencies for PCSK9. After 18 h, the medium
was removed, and the cells were washed with Opti-MEM
(Invitrogen). Purified PCSK9 protein was added to the cells in
100 l of mixture A (DMEM containing 10% lipoprotein-defi-
cient serum and 10 g/ml DiI-labeled LDL). To measure non-
specific binding, 100 l of mixture A that also contained 400
g/ml unlabeled LDL was added to control wells. The plates
were incubated at 37 °C for 6.5 h, and the cells were washed
quickly with Tris-buffered saline (Bio-Rad) containing 2mg/ml
BSA. The wash step was repeated, but this time the wash buffer
was incubated for 2 min with the cells. Finally, the cells were
quickly washed twice with Tris-buffered saline (without BSA)
and lysed in 100 l of radioimmune precipitation assay buffer.
The lysate was transferred to a 96-well black plate (Thermo
LabSystems), and fluorescence was measured using a Spectra-
MAX tunable spectrofluorometer (Molecular Devices) at an
excitationwavelength of 520 nmand an emissionwavelength of
580 nm. Total cellular protein was measured in each well using
the BCAprotein assay, and the fluorescence units were normal-
ized to total protein. The amount of specific LDL uptake (spe-
cific counts) is the difference between the total counts meas-
ured (in the absence of unlabeled LDL) and the counts
measured in the presence of an excess of unlabeled LDL (non-
specific background fluorescence). The amount of PCSK9 pro-
tein required for 50% inhibition of DiI-labeled LDL uptake
(EC50) was determined by fitting data to a sigmoidal dose-re-
sponse curve using nonlinear regression (GraphPad Software
Inc.).
PCSK9-LDLR Binding Affinity Measurements
Surface Plasmon Resonance (Biacore)—The interaction
between the LDLR ectodomain and wild-type PCSK9 or the
D374Y, S127R, and R46L variants was studied by surface plas-
mon resonance detection using a Biacore 3000 instrument (20,
21). A commercial LDLR ectodomain (residues 22–788; 10
g/ml in 10 mM sodium acetate, pH 5.0; R&D Systems) was
coupled to a research-grade carboxymethylated dextran sensor
chip (CM5, Biacore) using the amine coupling kit supplied by
the manufacturer to give surface densities of 150 resonance
units.Wild-type andmutant PCSK9 proteins were injected at a
concentration range of 0.03–2.0 M in a running buffer of 25
mMHEPES, pH 7.4, 150mMNaCl, and 0.1 mMCaCl2. For stud-
ies at acidic pH, experiments were carried out in 25mM sodium
acetate, pH 5.3, 150 mM NaCl, and 0.1 mM CaCl2 with PCSK9
concentrations spanning 0.03–0.5 M. Injections were per-
formed at 25 °C with flow rates of 40 l/min. Sensor chip sur-
faces were regenerated with 50 mM HCl for 3 s. The LasR
ligand-binding domain was used as a control to exclude non-
specific binding of the PCSK9 protein to immobilized LDLR.
Competition experiments between wild-type PCSK9 and LDL
particles for binding LDLRwere performed by incubating sam-
ples of LDLR with increasing concentrations of wild-type
PCSK9 (0–2 M) before injection over immobilized LDL parti-
cles. The primary data were analyzed using BIAevaluation Ver-
sion 4.1 software. Base lines were adjusted to zero for all curves,
and injection start times were aligned. The reference sensor-
grams were then subtracted from the experimental sensor-
grams to yield curves representing specific binding. All of the
kinetic datawere fit by assuming a simple 1:1 reactionmodel for
interaction between soluble analyte and immobilized ligand,
equivalent to the Langmuir isotherm for adsorption to a
surface.
Steady-state analysis was used to obtain thermodynamic
dissociation constants (KD) at pH 7.4. For each single titration,
simultaneous fitting of all the dissociation curves was used to
obtain koff values. kon values were calculated from KD and koff
values (KD  koff/kon). For the binding data at pH 5.3, kon and
koff were obtained by separate fitting of all the association and
dissociation curves of each titration, respectively. These kinetic
constants were then used to calculate the KD values.
TR-FRET—PCSK9-LDLR interactions were also studied by
TR-FRET (22, 23). This involved preparing fluorescently
labeled LDLR, PCSK9, and anti-V5 monoclonal antibody to
PCSK9-V5-His as described above. TR-FRET experiments
were carried out in 96-well blackMicrofluor-2U-bottomplates
(Dynex Technologies). Samples were 50-l total volume in 10
mM HEPES, pH 7.4, 150 mM NaCl, 0.1 mM CaCl2, and 0.05%
(w/v) BSA. The concentrations of reagents are as noted in indi-
vidual experiments, except for europium-labeled LDLR, for
which the stated concentration is the maximum assuming
100% recovery after labeling. Regardless of the putative concen-
tration, europium-labeled LDLR was used at 20,000–40,000
total counts at 620 nm. All materials were prepared in-house as
described, except for VLDL, which was purchased commer-
cially (Intracel). Samples were read using a BMG LabSystems
Rubystar Reader set to read 20 flashes/well with a 50-s inte-
gration delay and a 200-s integration time for a total read time
of 1100ms/well. Data are reported as the ratio of (counts at 665
nm/counts at 620 nm) 10,000.
PCSK9 Cellular Uptake
Cells treated with Alexa Fluor 647-labeled PCSK9 were
imaged as follows. CHO cells were plated on poly-D-lysine-
coated 96-well optical CVG sterile black plates (Nunc) at a den-
sity of 20,000 cells/well. Cells were plated in F-12K medium
(nutrient mixture, Kaighn’s modification (1)) (Invitrogen)
containing 100 units of penicillin and 100 g/ml streptomycin
sulfate and supplemented with 10% FBS. Plates were incubated
overnight at 37 °C and 5% CO2. The following morning, the
medium was removed and replaced with 100 l of F-12K
mediumcontaining 100 units of penicillin and 100g/ml strep-
tomycin sulfate. After 18 h, the medium was removed. Purified
PCSK9 protein was labeled with Alexa Fluor 647 as described
under “Experimental Procedures.” Alexa Fluor 647-labeled
PCSK9 (1, 5, or 20g/ml) was added in 50l of F-12Kmedium
containing 10% lipoprotein-deficient serum to the cells. The
plates were incubated at 37 °C for 4 h, and the cells werewashed
quickly with Tris-buffered saline before imaging. To label cel-
lular nuclei, Hoechst 33342 at a final concentration of 0.1g/ml
was added to eachwell. The plateswere run on anOpera imager
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(Evotec Technologies GmbH, Hamburg, Germany) with a40
water immersion objective. Images were captured using excita-
tion wavelengths of 405 nm for fluorescent nuclei and 635 nm
for Alexa Fluor 647-labeled PCSK9. For eachwell, 11 individual
fields containing 500 cells were captured for two emission
wavelengths. The data were analyzed using a customized algo-
rithm written using the Acapella language (Evotec Technolo-
gies GmbH). The algorithm identified and marked the nuclear
and cytoplasmic areas of individual cells, followed by measure-
ment of the total cytoplasmic intensity of the cell. The intensity
was expressed in arbitrary fluorescent units.
RESULTS
Expression and Purification of Gain- and Loss-of-function
Mutant PCSK9 Proteins—Several mutations within PCSK9
that are associated with low or high levels of circulating LDL-C
in humans have been described, and experiments in animals
and cell culture indicate that PCSK9 action leads to degradation
of the LDLR protein (14, 15, 17, 24). Notably, recent studies
using gel-based methods have shown that PCSK9 binds specif-
ically to LDLR in vitro and that the gain-of-function mutant
D374Yhas greater affinity for LDLR (6).We have expanded this
work to understand and compare the effects of wild-type
PCSK9, gain-of-function mutants S127R and D374Y, and loss-
of-function mutant R46L on cellular LDL uptake, a measure of
LDLR function. Several stable HEK293 cell lines expressing
wild-type PCSK9 or loss-of-function (R46L) or gain-of-func-
tion (S127R andD374Y)mutationswere generated. In addition,
a control HEK293 cell line stably expressing vector alone
(pcDNA) was also created. The PCSK9 proteins contained
C-terminal V5 andHis epitope tags, which enabled their detec-
tion and subsequent purification.
Secreted PCSK9 proteinswere purified from themedia of the
stable HEK293 cell lines by affinity chromatography (TALON),
followed by size exclusion and ion exchange (Mono Q) chro-
matography. Following purification, SDS-PAGE and Coomas-
sie Blue staining showed that all PCSK9 proteins were highly
pure (90%) (Fig. 1). Consistent with previously published data
(6) the purified proteins consisted of the mature PCSK9 frag-
ment containing the catalytic and C-terminal domains (63
kDa) and the prodomain (17 kDa). The fact that the two
domains co-purified indicates that the affinity between these
domains is very strong even after secretion. Notably, there was
no evidence of further processing of the PCSK9 prodomain,
which is typically required for activation of proprotein conver-
tase protease activity (25, 26). Preparations of this highly pure
PCSK9 protein were used in further biochemical analysis of
PCSK9 function.
Exogenously Added PCSK9 Lowers Cellular LDL Uptake in
Different Cell Lines—Recent work has shown that the transfer
ofmedium fromPCSK9-expressing cells to fresh cells results in
down-regulation of both the number of LDLRs and, as a direct
consequence, cellular LDLuptake (6, 19). In this study, we pres-
ent a detailed analysis of the effects of purified secreted wild-
type PCSK9 on LDL uptake in different cell lines.We examined
the ability of wild-type PCSK9 to reduce LDL uptake in an
HEK293 cell line stably expressing an empty pcDNA3.1 vector,
a human hepatocyte cell line (HepG2), and a CHO cell line.
Analysis of basal LDL uptake by these cell lines demonstrated
that all three cell lines internalize LDL to comparable levels,
with HEK293 cells showing a slightly reduced level of LDL
uptake compared with HepG2 and CHO cells (Fig. 2A). As
shown in Fig. 2B, the addition of purified PCSK9 to the
media of HEK293-pcDNA3.1, HepG2, and CHO cell lines
reduced the amount of LDL uptake in a dose-dependent
manner. The potency (EC50) of PCSK9 in lowering LDL uptake
was 2-fold weaker in CHO cells (EC50  129  19 nM; 9.7
g/ml) and similar in HepG2 cells (EC50  64  16 nM; 4.8
g/ml) compared with HEK293 cells (EC50  61  21 nM;
4.6 g/ml) (Fig. 2B).
LDL Uptake Lowering Potencies of Wild-type PCSK9 and
Mutants R46L, S127R, and D374Y Correlate with LDL-C Levels
in Humans Carrying ThoseMutations—To determine whether
the relative potencies of PCSK9 mutations in LDL uptake may
help explain their effects on LDL concentrations in humans
carrying such mutations, we compared the potency of various
PCSK9 mutants with that of the wild-type form of the protein.
As shown in Fig. 2C, LDL uptake was reduced when increasing
amounts of PCSK9 protein were added to the media. The
amount of LDL uptake was reduced by 50% at a concentration
FIGURE 1.Purification of PCSK9proteins secreted fromHEK293 cell lines.
Shown is a Coomassie Blue-stained gel of purified PCSK9 proteins. Stable
HEK293 cell lines were maintained in 1 DMEM containing 1 mg/ml G418
supplemented with 10% FBS. Following several days of growth, the medium
was collected, and PCSK9 protein was purified through several chromato-
graphic steps (TALON, size exclusion, and RESOURCE Q) as described under
“Experimental Procedures”. The results shown are from 1 g of recombinant
PCSK9 protein loaded per well. Cat and Pro indicate the mature fragments of
PCSK9 including the catalytic and cysteine-rich C-terminal domains and the
prodomain of PCSK9, respectively.WT, wild-type PCSK9.
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of 61 21 nM (4.6 g/ml) for wild-type PCSK9 protein (Table
1). By comparison, both the S127R andD374Y gain-of-function
proteins were significantly more effective in reducing the
amount of LDL uptake by cells. S127R was5-fold more effec-
tive in reducing LDL uptake (EC50 11 4.6 nM; 0.86 g/ml),
and D374Y was25-fold more effective (EC50 2.3 0.9 nM;
0.18 g/ml) (Table 1). The ability of the R46L loss-of-function
mutant to reduce LDL uptake was similarly tested to determine
whether it is less effective than wild-type PCSK9 protein. The
R46L protein was slightly less effec-
tive than the wild-type protein in
reducing LDL uptake (EC50  81 
6.7 nM; 6.3 g/ml). Of note, the
potencies (EC50) of the different
PCSK9 proteins correlated linearly
with the LDL-C concentrations of
humans carrying such mutations
(Fig. 2D). A similar trend in poten-
cies was observed when the D374Y
gain-of-function mutant was added
to the HepG2 and CHO cell lines,
with the following results: HepG2
cells, EC50  3.5  1.6 nM (0.27
g/ml); and CHO cells, EC50 
6.9 2.3 nM (0.53g/ml). Together,
these data demonstrate that meas-
uring the ability of purified PCSK9
proteins to reduce cellular LDL
uptake provides a readout that cor-
relates with the ability of PCSK9 to
regulate LDLR function in vivo.
PCSK9 Directly Binds LDLR in a
pH-dependent Manner—The exper-
iments described above demon-
strate that secreted PCSK9 reduces
cellular LDL uptake in different cell
lines. A previous study using gel-
blotting techniques has shown that
PCSK9 binds LDLR specifically and
that the D374Y gain-of-function
mutant has greater affinity for
LDLR than does wild-type PCSK9 (6). Here, we use the meth-
ods of surface plasmon resonance (Biacore technology) and
TR-FRET tomeasure and compare thermodynamic and kinetic
parameters of LDLR binding by PCSK9, gain-of-function
mutants S127R and D374Y, and loss-of-function mutant R46L.
First, Biacore technology was used to measure the binding
affinities of wild-type PCSK9 and mutants for the immobilized
LDLR ectodomain at pH 7.4. A strong interaction between
LDLR and PCSK9, but not a control protein, was detected (Fig.
3A). Comparison of the thermodynamic dissociation constants
(KD) at pH 7.4 showed that the affinity of the gain-of-function
mutant D374Y for the receptor was 6–7 times higher than that
of thewild-type protein (Fig. 3,A andB; andTable 2), consistent
with the trend obtained by reported gel blotting studies (6). In
contrast, at pH 7.4, the other gain-of-function mutant, S127R,
bound LDLR similarly compared with wild-type PCSK9,
whereas the loss-of-function mutant R46L had a 2-fold weaker
affinity for LDLR compared with wild-type PCSK9 (Table 2).
LDL binds to LDLR at neutral pH on the cell surface, but the
complex dissociates at the low pH of the endosomes (pH 	 6)
(27–29). Therefore, we thought to determine whether the
PCSK9-LDLR interactionwould also be affected by exposure to
acidic pH. Biacore experiments were repeated at pH 5.3, and
the KD values for all mutants were obtained. Surprisingly, the
affinity of all PCSK9 proteins for LDLR at pH 5.3 was at least
150-fold higher than that at pH 7.4, resulting inKD values in the
FIGURE 2. Reduction of LDL uptake by exogenously added PCSK9 protein. A, analysis of DiI-labeled LDL
uptake by HEK293, HepG2, and CHO cell lines. Cells were grown and DiI-labeled LDL uptake was measured as
described under “Experimental Procedures.” B, purified PCSK9 protein inhibits LDL uptake in HEK293, HepG2,
and CHO cell lines. Each cell linewas grown in serum-freemedium for 18 h before the addition of the indicated
amounts of purified PCSK9 protein andDiI-labeled LDL. Following incubation for 6.5 h, cells werewashed, and
the amount of DiI-labeled LDL uptake wasmeasured as described under “Experimental Procedures.” The data
shown are representative of at least three independent experiments and are fit to a sigmoidal dose-response
curvebynonlinear regression.C, PCSK9gain-of-functionmutantsD374YandS127Rdecrease LDLuptakemore
efficiently than wild-type PCSK9 or loss-of-function mutant R46L. D, relationship between the apparent bio-
chemical potency of various PCSK9 mutants (horizontal axis) versus the LDL-C levels in humans bearing those
same mutations (vertical axis). Shown are the mean EC50 values determined in the cell-based assay of PCSK9
function and the mean LDL concentrations from human subjects found in published reports (7, 13, 44).
TABLE 1
LDL uptake results and relationship between EC50 values and LDL
concentrations in humans
The potencies of wild-type (WT) and mutant PCSK9 proteins in inhibiting LDL
uptake were determined with a pcDNA3.1 cell line as described under “Experimen-
tal Procedures.”
Genotype LDL uptake EC50a Gain/lossb LDL-Cc,d No. individuals
nM mg/dl
WT 61 21 137 37 9223
R46L 81 6.7 Loss 116 33 301
S127R 11 4.6 Gain 287 72 9
D374Y 2.3 0.9 Gain 437 158 13
a Concentration of PCSK9 protein at which 50% of LDL uptake was inhibited
(means S.D.).
b Indicates whether the PCSK9 mutation results in hypercholesterolemia (gain) or
hypocholesterolemia (loss).
c Denotes average LDL-C concentration present in plasma from individuals bearing
the indicated PCSK9 genotype.
d LDL-C concentrations for the following PCSK9 genotypes obtained as indicated:
wild-type PCSK9 (13), R46L (13), S127R (7), and D374Y (44).
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low nanomolar range (Table 2). Finally, similar to what was
observed at neutral pH, at pH 5.3, the R46Lmutant had a mod-
estly lower affinity (1.5–2-fold weaker). In contrast, the S127R
mutant showed a modestly higher affinity (2-fold stronger)
comparedwithwild-type PCSK9 at pH 5.3 (Table 2). To further
validate the results obtained by Biacore, TR-FRET-based
experiments (22, 23) were used to measure the interaction
between PCSK9 and LDLR. Specific fluorescence transfer was
detected between a Eu3-labeled LDLR ectodomain and
PCSK9 bound to Alexa Fluor 647-labeled anti-V5 antibody at
pH 6.8. As shown in Fig. 3C, the concentration of D374Y pro-
tein required for significant detec-
tion of PCSK9-LDLR-dependent
fluorescence was 36-fold lower
than that of wild-type PCSK9, indi-
cating a much higher affinity
between D374Y and LDLR.
Together, these experiments inde-
pendently show that the D374Y
mutant bound LDLR with greater
affinity than did wild-type PCSK9
(Fig. 3C).
PCSK9 Is Internalized by Cul-
tured Cells and the D374Y Mutant
Is Internalized More Efficiently
Compared with Wild-type PCSK9
and the S127R and R46L Mutants—
Immunoblot experiments have pre-
viously shown that wild-type
PCSK9 is internalized when added
to fresh cells and that the gain-of-
function mutant D374Y is internal-
ized more efficiently (6). To expand
on this work and to compare other
PCSK9 mutants, confocal micros-
copy was used to measure the rela-
tive uptake efficiencies of PCSK9
and gain-of-function mutants
D374Y and S127R and loss-of-func-
tion mutant R46L. To measure
PCSK9 internalization, we directly
labeled PCSK9 with Alexa Fluor
647. Labeling PCSK9with the dye did not significantly affect its
ability to reduce LDL uptake because the relative potency of
labeled PCSK9 was reduced modestly (3-fold) compared with
the unlabeled protein (data not shown). The uptake of DiI-
labeled LDL byCHOcells was significantly reduced in the pres-
ence of 20 g/ml Alexa Fluor 647-labeled wild-type or D374Y
protein (Fig. 4A, left panels), confirming the activity of Alexa
Fluor 647-labeled PCSK9 in lowering LDL uptake. To measure
PCSK9 uptake, CHO cells were incubated with Alexa Fluor
647-labeled PCSK9, and the uptake of PCSK9was quantified by
confocalmicroscopy (Fig. 4A, right panels). The uptake ofAlexa
Fluor 647-labeled wild-type PCSK9 protein by CHO cells was
detectable within 30 min after addition to cells (data not
shown). In addition to wild-type PCSK9 protein, Alexa Fluor
647-labeled gain-of-function (S127R and D374Y) and loss-of-
function (R46L) proteins were also taken up by cells (Fig. 4).
Based on experiments in which a subsaturating concentration
of Alexa Fluor 647-labeled PCSK9 was added to cells (1 g/ml)
and the relative intensities of internalized Alexa Fluor 647-la-
beled PCSK9 protein within cells, the D374Y protein was inter-
nalized 3-fold more efficiently than the wild-type protein,
whereas both the S127R and R46L mutants were taken up by
cells to a similar extent as the wild-type protein (Fig. 4B). A
similar pattern of PCSK9 uptake was also observed using
HEK293 cells (data not shown), indicating that the D374Y pro-
tein is internalized more efficiently by cells.
FIGURE 3. PCSK9 binds specifically to LDLR. A, solution-phase PCSK9-LDLR binding measured by surface
plasmon resonance (Biacore). A representative Biacore sensorgram shows the response over time (resonance
units (RU)) during the binding at pH 7.4 of purified recombinant wild-type PCSK9 to immobilized recombinant
LDLR ectodomain. B, titration curve for binding of the purified PCSK9mutant D374Y to immobilized recombi-
nant LDLR ectodomain at pH 7.4. A slower dissociation of the complex was observed for the gain-of-function
mutant D374Y compared with wild-type PCSK9. C, TR-FRET indicates that D374Y is6-fold more potent than
the wild-type protein in binding to europium-labeled LDLR. A preformed complex of Alexa Fluor 647-labeled
anti-V5 antibody (40 nM) and Eu3-labeled recombinant LDLR ectodomain (15 nM)was combinedwith increas-
ing amounts of purified wild-type PCSK9 protein or the D374Y mutant at pH 7.4. The specific fluorescence
transfer (Ratio) was detected between a europium-labeled LDLR ectodomain and PCSK9 bound to Alexa Fluor
647-labeled anti-V5 antibody.
TABLE 2
LDLR binding affinities for wild-type PCSK9 andmutants at pH 7.4
and 5.3
The binding affinities of wild-type and mutant PCSK9 proteins for LDLR were
determined at pH 7.4 and 5.3 as described under “Experimental Procedures.”
Genotype kon xWT
a
kon koff
xWT
koff KD
xWT
KD
M1 s1 s1 nM
pH 7.4
WT 1.86 103 1.0 1.17 103 1.0 628 1.0
R46L 5.26 103 2.8 6.31 103 5.3 1200 1.9
S127R 1.19 104 6.3 7.72 103 6.5 648 1.03
D374Y 4.57 103 2.4 4.62 104 0.4 101 0.16
pH 5.3
WT 4.73 105 1.0 1.97 103 1.0 4.19 1.0
R46L 1.38 105 0.3 8.72 103 4.4 6.33 1.5
S127R 8.13 105 1.7 1.42 103 0.7 1.76 0.4
D374Y 6.74 105 1.4 3.64 104 0.2 0.54 0.1
a -Fold change from wild-type PCSK9 at the indicated pH.
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LDL and VLDL Decrease LDLR Binding Affinity for PCSK9—
Both LDL and VLDL particles bind LDLR and are released
within endosomes for catabolism. In light of the observed
interaction between LDLR and PCSK9, we investigated the
effects of LDL and VLDL on the affinity of PCSK9 for LDLR
using biosensor- and TR-FRET-based experiments. For the
first set of experiments, PCSK9
was immobilized on a sensor chip,
and the LDLR ectodomain was
injected at a single concentration.
The sensogram obtained was con-
sistent with the interaction previ-
ously observed between immobi-
lized LDLR and injected PCKS9
(data not shown). We then tested
whether LDL could bind directly
to immobilized PCSK9; however,
no interaction was detected (max-
imum concentration of injected
LDL was 65 g/ml (130 nM)) (data
not shown). We then immobilized
LDL on the sensor chip and
observed specific binding to LDLR
(Fig. 5A), but not to PCSK9 (up to
1 M added). The KD of LDL for
LDLR in this experiment was 11
nM (data not shown), a value con-
sistent with published reports
(40–42). Finally, a direct competi-
tion experiment between LDL and
PCSK9 for LDLR binding was per-
formed (Fig. 5A). In this experi-
ment, LDLR (130 nM) was first
incubated at room temperature
with increasing concentrations of
wild-type PCSK9 protein, and
samples were then injected over
immobilized LDL particles. A
comparison of the sensorgrams
showed a diminishing response
with increasing PCSK9 concentra-
tions (Fig. 5A), indicating that
PCSK9 decreases the affinity of
LDLR for LDL either by causing a
conformational change on the
receptor (i.e. allosteric effect) or
by reducing the accessibility of the
LDL-binding site on LDLR.
To confirm the effects of LDL on
PCSK9-LDLR binding, we titrated
LDL and VLDL particles to a pre-
formed fluorescently labeled LDLR-
PCSK9 complex at pH 7.4 (see
“Experimental Procedures”). As the
amount of either LDL or VLDL was
increased in the reaction, the
TR-FRET ratio between the pre-
formed LDLR-PCSK9 complexes
decreased (Fig. 5B), indicating that these lipoprotein particles
cause dissociation of the complex. LDL was2-fold more effi-
cient at disrupting the LDLR-PCSK9 complex (IC50 84 15
g/ml) compared with VLDL (IC50 134 35g/ml). There-
fore, LDL and VLDL not only bind tightly to LDLR, but also
affect PCSK9 binding to LDLR.
FIGURE 4. Cellular internalization of wild-type andmutant PCSK9. A, imaging of DiI-labeled LDL and wild-
type PCSK9 and mutant D374Y protein uptake into CHO cells. Left panels, CHO cells were incubated with 10
g/ml DiI-labeled LDL (DiI-LDL) in the presence or absence of 20 g/ml (250 nM) Alexa Fluor 647-labeled
wild-type (WT) PCSK9 or mutant D374Y protein for 4 h before images were obtained by confocal microscopy.
Right panels, CHO cells were incubated with 5 g/ml (62.5 nM) Alexa Fluor 647-labeled PCSK9 (AF-PCSK9)
proteins. Images shown are at 40 scale. B, quantification of wild-type and mutant PCSK9 uptake into CHO
cells. The amount of Alexa Fluor 647-labeled PCSK9uptake into cellswas quantified as describedunder “Exper-
imental Procedures.” The results shownarewith 1g/ml (12.5 nM) labeledPCSK9addedandare representative
of at least three independent experiments.
FIGURE5.LDLcompeteswithPCSK9 forLDLRbindingand inhibitsPCSK9 function.A, Biacore sensorgrams
show that the binding of LDLR to immobilized LDL particles is reduced when LDLR (130 nM) is preincubated
with increasing concentrations of wild-type PCSK9 protein, indicating a competition between PCSK9 and LDL
for LDLR binding. B, both LDL and VLDL disrupt the complex between europium-labeled soluble LDLR and
wild-type PCSK9. In this titration, increasing amounts of either VLDL or LDL were titrated into reactions con-
taining apreformed complex of Alexa Fluor 647-labeled anti-V5 antibody (40nM),wild-type PCSK9 (80nM), and
Eu3-labeled recombinant LDLR (12 nM) at pH 7.4. Data are the means  S.D. of triplicates, Curve fits are
three-parameter fits with the bottom set as the no-PCSK9 background. C, the results from LDLR Western blot
analysis show that the effects of exogenous PCSK9 on LDLR degradation are inhibited by LDL in a dose-de-
pendentmanner. The pcDNA3.1 cell linewas treatedwith orwithout 25g/ml PCSK9 and increasing amounts
of LDL. The data shown are representative of three independent experiments. In each lane, the sample loaded
onto the gel was normalized for total cellular protein. RU, resonance units.
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LDL Inhibits PCSK9-dependent Effects on Cellular LDLR
Degradation—To examine the effects of LDL on PCSK9 func-
tion in cell culture, PCSK9was added toHEK293 cells for 6 h in
either the absence or presence of increasing amounts of LDL
(1.6–100g/ml), and LDLRwas detected inwhole cell lysate by
Western blotting (Fig. 5C). In the absence of LDL, PCSK9
degraded whole cell LDLR to levels below detection; however,
at LDL concentrations of 25 g/ml and above, the effects of
PCSK9 on LDLR degradation were partially blocked (Fig. 5C).
Notably, the addition of LDL alone did not affect the amount of
whole cell LDLRprotein levels (data not shown), indicating that
the increase in LDLR observed in the presence of PCSK9 and
LDL is likely due to LDL preventing PCSK9-dependent degra-
dation of LDLR. Together, these results and the in vitroPCSK9-
LDLR binding data suggest that LDL exerts an inhibitory effect
on the PCSK9-dependent degradation of LDLR by modulating
PCSK9-LDLR binding.
DISCUSSION
In this study, we have presented biochemical and cell-based
data that deepen our understanding of themechanismbywhich
secreted PCSK9 promotes LDLR degradation. Recent work has
shown that, when added to fresh cultured HepG2 cells, pro-
cessed PCSK9 lowers cell-surface LDLR and whole cell LDLR
(6). We have confirmed this result and expanded upon it by
showing that highly purified and processed PCSK9 lowers cel-
lular LDL uptake in three different cell lines (HEK293, HepG2,
and CHO). In our studies, all three cell lines had comparable
basal LDL uptake levels that was lowered in a dose-dependent
manner by exogenously added wild-type PCSK9, with themax-
imum potency achieved in HEK293 cells (EC50  61 nM; 4.6
g/ml), followed byHepG2 cells (EC50 64 nM; 4.8g/ml) and
CHO cells (EC50  129 nM; 9.7 g/ml) (Fig. 2B). The potency
(EC50 4.6g/ml) of wild-type PCSK9 in lowering LDLuptake
in HepG2 cells was3-fold weaker than the potency for LDLR
degradation recently reported by Horton and co-workers (6).
This discrepancy is likely related to the differences in the
lipoprotein content of the incubationmedia. In our LDL uptake
assay system, PCSK9 was added in the presence of 10 g/ml
DiI-labeled LDL to medium containing 10% lipoprotein-defi-
cient serum, whereas the LDLR degradation experiments were
carried out with medium lacking LDL and containing 5%
lipoprotein-deficient serum. We consistently found that the
EC50 for LDLR degradation by PCSK9 was shifted 3-fold
towardweaker potencies in the presence of 10g/ml LDL (data
not shown).
Although several studies have reported that PCSK9 is func-
tionally active in HEK293 and HepG2 cells (5, 6, 15, 19), one
report indicates that CHOcells stably expressing PCSK9 do not
have lower LDLR compared with mock cells, indicating that
PCSK9 is not functional in CHO cells (15). In this study, we
used a functional cell-based assay (Fig. 2) and confocal imaging
microscopy (Fig. 4) to show that wild-type PCSK9 and the gain-
of-function mutant D374Y are functionally active in lowering
LDL uptake and degrading LDLR in CHO cells. Our results
suggest that either the levels of PCSK9 expression were too low
and/or the concentration of PCSK9 in the medium was subop-
timal in the reported CHO cell line to have an impact on LDLR
protein levels.
Our studies focused on two gain-of-functionmutants (S127R
and D374Y) and one loss-of-function mutant (R46L) that com-
monly occur in the human population (7–9, 12, 13, 30) and that
undergo processing and secretion (15, 30, 31). Highly purified
processed forms of PCSK9 proteins lower cellular LDL uptake
when added to HEK293 cells with relative potencies that lin-
early correlate with plasma LDL-C levels in humans (Fig. 2D
andTable 1). The potencies of gain-of-functionmutantsD374Y
(2.3 0.9 nM; 0.18g/ml) and S127R (11 4.6 nM; 0.86g/ml)
were significantly greater than those of wild-type PCSK9 (61
21 nM; 4.6 g/ml) and the loss-of-function mutant R46L (81
6.7 nM; 6.3 g/ml). In this work, we observed that the S127R
mutantwas5-foldmore potent thanwild-type PCSK9 in low-
ering LDL uptake inHEK293 cells; a similar trendwas observed
in HepG2 cells as well (data not shown). In comparison, it has
been reported that adenoviral overexpression of wild-type
PCSK9 and S127R in mice promotes similar levels of hepatic
LDLR degradation (15). This apparent discrepancy may result
from dramatic overexpression induced by the adenoviruses,
which may result in circulating levels of PCSK9 that are sever-
alfold above the EC50 values of both proteins for lowering
LDLR.
The relative LDL uptake lowering potencies of D374Y,
S127R, wild-type PCSK9, and R46L (D374Y  S127R  wild-
type PCSK9  R46L) linearly correlate with LDL-C levels
reported in humans carrying those mutations (Table 1) and
parallel their LDLR binding affinities at pH 5.3 (Table 2). In
comparison, the relative efficiency of cell internalization by
PCSK9 and itsmutants (D374Y S127Rwild-type PCSK9
R46L)more closely parallels their LDLR binding affinities at pH
7.4. These comparisons suggest that, although PCSK9-LDLR
binding at the neutral pH of plasma is the rate-limiting step for
PCSK9 entry into cells, PCSK9-LDLR binding at the acidic pH
of endosomes also significantly influences PCSK9 activity on
cellular LDL uptake. It is also likely that factors other than
LDLR binding affinity contribute to regulate the functional
activity of PCSK9 and its missense mutants. For example, it has
been reported that the S127R protein is not processed as effi-
ciently as wild-type PCSK9 or other PCSK9 missense mutants
(5, 15), resulting in comparably less processed S127R protein
secreted from cells. Despite this reduction in secretion, the
S127R allele results in hypercholesterolemia (7). In addition,
one report has found that wild-type PCSK9 can be cleaved by
furin, but that gain-of-function mutants R218S, F216L, and
D374Y are less susceptible to processing by furin (31). There-
fore, it is likely that, in addition to PCSK9-LDLR affinity, other
factors influence the activity of wild-type PCSK9 and its mis-
sense mutants in lowering LDLR levels in vivo.
LDLR binds its ligands (LDL, VLDL, and C7, a monoclonal
antibody that recognizes the LDLR ligand-binding domain) at
the cell surface, followed by internalization of the complex
through endocytosis in clathrin-coated pits (28, 32, 33). At the
low pH of endosomes (pH	 6), LDLR undergoes a conforma-
tional change leading to dissociation of the LDLR-ligand com-
plex, recycling of the receptor to the cell surface, and degrada-
tion of the ligand in lysosomes (28, 29). In agreement with
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recent work (6, 34), we have shown that PCSK9 interacts
directly with LDLR (Fig. 3) and is internalized by cells (Fig. 4).
However, we have shown that PCSK9 behaves quite differently
from the other well characterized LDLR ligands in that its affin-
ity for the receptor is significantly enhanced (150-fold) at pH
5.3 compared with neutral pH (Table 2). It has been shown that
dissociation of LDLR from LDL is required for LDLR recycling
(27, 35); similarly, lack of dissociation of the LDLR-PCSK9
complex in the endosomes may prevent LDLR recycling and
lead to shuttling of the complex to lysosomes for eventual deg-
radation. Furthermore, a similar mechanism for LDLR degra-
dation has been demonstrated previously using an LDLR dele-
tion mutant lacking the epidermal growth factor precursory
homology domain. This mutant form of the receptor is dis-
played at the cell surface, binds VLDL (but not LDL), and is
internalized into cells like the wild-type receptor; however, it
cannot dissociate from VLDL in endosomes and, instead of
being recycled, is directed to the lysosome for degradation (27,
35). Of note, degradation of LDLR upon overexpression of
PCSK9 in cultured cells is blocked by the addition of NH4Cl,
indicating a role for a pH-sensitive compartment such as the
lysosome in PCSK9-dependent LDLR degradation (5, 36).
Although we cannot exclude that PCSK9 acts as a protease
upon LDLR or another protein following internalization by
cells and/or entry into an acidic microenvironment such as the
endosomal or lysosomal compartment, we did not find any evi-
dence of PCSK9-dependent LDLR degradation using purified
proteins in vitro at both neutral and acidic pH (data not shown).
Moreover, we and others (6) have not been successful in detect-
ing PCSK9-specific cleavage of any peptide substrate, including
those resembling the PCSK9 site of processing (FAQ2SIP).
Together, these data suggest amodel inwhich PCSK9 functions
as a shuttling protein by forcing the trafficking of LDLR to the
lysosomes for degradation.
An important question is whether PCSK9 works during
secretion out of the cell or during internalization (37). Overex-
pression of PCSK9 in the livers ofmice lackingARH (autosomal
recessive hypercholesterolemia), a putative adaptor protein
required for LDLR endocytosis (38, 39), results in a reduction of
hepatic LDLRprotein levels (15). This indicates that PCSK9 can
reduce LDLR protein during transport to the cell surface or
when LDLR is on the cell surface. However, in this system,
PCSK9 was dramatically overexpressed, which could result in
activation of an alternative pathway of PCSK9-dependent
LDLR degradation. In comparison, our study and recent work
(6, 19) indicate that processed secreted PCSK9 is functionally
active because it can lower cell-surface LDLRprotein andwhole
cell LDLR levels when added to fresh cultured cells. The ability
of secreted PCSK9 to lower LDLR protein levels requires LDLR
endocytosis, as there is no effect of PCSK9 addition to cultured
cells lacking the ARH adaptor protein (6). Although our
results show that secreted and internalized PCSK9 can lower
LDLR function, further studies will be required to address
the relative roles of PCSK9 in lowering LDLR before or after
secretion in vivo.
Our data indicating that LDL and VLDL affect the LDLR
binding affinity for PCSK9 and the partial inhibitory effect of
LDL in cell culture suggest that the contribution of secreted
PCSK9 to LDLR lowering may be attenuated by the levels of
plasma LDL. If the PCSK9 predominant site of action on LDLR
is on the cell surface, then it is likely that circulating levels of
LDL decrease the affinity of LDLR for PCSK9 by causing a con-
formational change in the receptor (i.e. allosteric effect) or by
reducing the accessibility of PCSK9 to its binding site on LDLR.
In fact, the binding affinity of wild-type PCSK9 for LDLR (KD
628 nM) is significantly lower than that of LDL for LDLR (5–25
nM) (40–42), and the human plasma concentrations of PCSK9
(2–10 nM; 0.5 g/ml) (6) are much lower than that of LDL
(2.8 M apoB; 1500 g/ml) (43). However, complete inhi-
bition of PCSK9 was not achieved even when excess LDL was
used (data not shown), suggesting that additional factors such
as the local concentrations of PCSK9 andLDL at the cell surface
or an accessory cell-surface proteinmay play a role inmodulat-
ing the PCSK9-LDLR interaction. The involvement of other
factors such as a cell-surface accessory protein would also
explain the discrepancy between the levels of plasma PCSK9
and the EC50we obtained in our cell-based assay. In conclusion,
we have shown that LDL partially inhibits the LDLR lower-
ing activity of plasma PCSK9; moreover, we have shown that
PCSK9 and LDLR form a highly stable complex at acidic pH,
suggesting that PCSK9 prevents LDLR recycling and ulti-
mately causes LDLR degradation by directing the receptor to
the lysosomes.
Addendum—While this manuscript was under revision, two studies
were published that show pH-dependent binding of PCSK9 to LDLR
(45, 46).
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